Table 2.
Adverse event rates per 12 month period adjusted for exposure.
Period (months) | Control* | 0–12 | 12–24 | 24–36 | 36–48 | >48 |
---|---|---|---|---|---|---|
| ||||||
Subject-years exposure | 15.0 | 69.0 | 61.1 | 59.2 | 57.8 | 39.9 |
| ||||||
Adverse Events | ||||||
Number of events | 319 | 643 | 374 | 300 | 349 | 184 |
Event rate** | 2127 | 931.9 | 612.1 | 506.8 | 603.8 | 461.1 |
| ||||||
Serious AEs | ||||||
Number of events | 7 | 31 | 28 | 15 | 26 | 7 |
Event rate** | 46.7 | 44.9 | 45.8 | 25.3 | 45.0 | 17.5 |
Subjects who received placebo in the placebo-controlled, double-blind mepolizumab trial (MHE100185)
Events per 100 subject-years exposure within period.